Does the media favor KOD or PTGX?

In the previous week, Kodiak Sciences had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 18 mentions for Kodiak Sciences and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.02 beat Kodiak Sciences' score of -0.05 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KYMR or KOD?

In the previous week, Kodiak Sciences had 9 more articles in the media than Kymera Therapeutics. MarketBeat recorded 18 mentions for Kodiak Sciences and 9 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.24 beat Kodiak Sciences' score of -0.05 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, KOD or SMMT?

Summit Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.19 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is KOD or SMMT more profitable?

Summit Therapeutics' return on equity of -168.94% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -273.23% -85.48% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor KOD or SMMT?

In the previous week, Kodiak Sciences had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 18 mentions for Kodiak Sciences and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.37 beat Kodiak Sciences' score of -0.05 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KOD or KRYS?

In the previous week, Kodiak Sciences had 11 more articles in the media than Krystal Biotech. MarketBeat recorded 18 mentions for Kodiak Sciences and 7 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.30 beat Kodiak Sciences' score of -0.05 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, NUVL or KOD?

Nuvalent is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Kodiak Sciences N/A N/A -$229.97M -$4.19 N/A

Is NUVL or KOD more profitable?

Nuvalent's return on equity of -40.11% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Kodiak Sciences N/A -273.23% -85.48%

Kodiak Sciences (KOD) Competitors

$38.33 -1.51 (-3.79%)

As of 08/21/2026 04:00 PM Eastern

Compare

KOD vs. PTGX, KYMR, SMMT, KRYS, and NUVL

Should you buy Kodiak Sciences stock or one of its competitors? Kodiak Sciences's main competitors and comparable companies include Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), Summit Therapeutics (SMMT), Krystal Biotech (KRYS), and Nuvalent (NUVL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kodiak Sciences compare to Protagonist Therapeutics?

Kodiak Sciences (NASDAQ:KOD) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Protagonist Therapeutics has a net margin of 29.40% compared to Kodiak Sciences' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Protagonist Therapeutics	29.40%	12.03%	11.23%

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Kodiak Sciences had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 18 mentions for Kodiak Sciences and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.02 beat Kodiak Sciences' score of -0.05 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences presently has a consensus target price of $48.14, indicating a potential upside of 25.60%. Protagonist Therapeutics has a consensus target price of $140.53, indicating a potential downside of 8.93%. Given Kodiak Sciences' higher probable upside, equities analysts clearly believe Kodiak Sciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94

Protagonist Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Protagonist Therapeutics	$46.02M	216.99	-$130.15M	$1.03	149.83

Kodiak Sciences has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Kodiak Sciences on 12 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Kymera Therapeutics presently has a consensus price target of $125.65, indicating a potential upside of 4.88%. Kodiak Sciences has a consensus price target of $48.14, indicating a potential upside of 25.60%. Given Kodiak Sciences' higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

89.1% of Kodiak Sciences shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kymera Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Kodiak Sciences has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	254.05	-$311.35M	-$3.24	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

Kodiak Sciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Kodiak Sciences	N/A	-273.23%	-85.48%

In the previous week, Kodiak Sciences had 9 more articles in the media than Kymera Therapeutics. MarketBeat recorded 18 mentions for Kodiak Sciences and 9 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.24 beat Kodiak Sciences' score of -0.05 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kodiak Sciences beats Kymera Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to Summit Therapeutics?

Kodiak Sciences (NASDAQ:KOD) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kodiak Sciences has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

Kodiak Sciences presently has a consensus target price of $48.14, suggesting a potential upside of 25.60%. Summit Therapeutics has a consensus target price of $24.25, suggesting a potential upside of 84.24%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

Summit Therapeutics' return on equity of -168.94% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Kodiak Sciences had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 18 mentions for Kodiak Sciences and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.37 beat Kodiak Sciences' score of -0.05 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summit Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Summary

Kodiak Sciences beats Summit Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Kodiak Sciences compare to Krystal Biotech?

Kodiak Sciences (NASDAQ:KOD) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Kodiak Sciences has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Kodiak Sciences' net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Krystal Biotech	54.82%	19.34%	17.65%

In the previous week, Kodiak Sciences had 11 more articles in the media than Krystal Biotech. MarketBeat recorded 18 mentions for Kodiak Sciences and 7 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.30 beat Kodiak Sciences' score of -0.05 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Krystal Biotech	$389.13M	26.36	$204.83M	$7.98	43.43

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kodiak Sciences currently has a consensus price target of $48.14, suggesting a potential upside of 25.60%. Krystal Biotech has a consensus price target of $365.40, suggesting a potential upside of 5.43%. Given Kodiak Sciences' higher possible upside, equities analysts clearly believe Kodiak Sciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Krystal Biotech beats Kodiak Sciences on 11 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Nuvalent's return on equity of -40.11% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Kodiak Sciences	N/A	-273.23%	-85.48%

In the previous week, Kodiak Sciences had 18 more articles in the media than Nuvalent. MarketBeat recorded 18 mentions for Kodiak Sciences and 0 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.00 beat Kodiak Sciences' score of -0.05 indicating that Nuvalent is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvalent	Neutral
Kodiak Sciences	Neutral

Nuvalent has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Nuvalent presently has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Kodiak Sciences has a consensus target price of $48.14, suggesting a potential upside of 25.60%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Nuvalent is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Kodiak Sciences beats Nuvalent on 9 of the 13 factors compared between the two stocks.

Get Kodiak Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOD vs. The Competition

Export

Metric	Kodiak Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.41B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-9.15	11.62	272.60	24.25
Price / Sales	N/A	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	39.52	16.80	13.05	6.20
Net Income	-$229.97M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-7.30%	3.29%	2.09%	0.08%
1 Month Performance	-6.56%	8.23%	6.64%	3.88%
1 Year Performance	275.78%	55.05%	25.02%	16.98%

Kodiak Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOD Kodiak Sciences	2.5132 of 5 stars	$38.33 -3.8%	$48.14 +25.6%	+275.8%	$2.41B	N/A	N/A	90	News Coverage Analyst Revision
PTGX Protagonist Therapeutics	2.0099 of 5 stars	$158.49 -0.1%	$140.53 -11.3%	+168.5%	$10.09B	$281.99M	151.43	120	Analyst Upgrade
KYMR Kymera Therapeutics	1.4938 of 5 stars	$121.02 -0.3%	$125.65 +3.8%	+171.7%	$10.08B	$105M	N/A	170	News Coverage Positive News
SMMT Summit Therapeutics	3.809 of 5 stars	$12.74 -0.3%	$24.25 +90.2%	-49.8%	$10.04B	N/A	N/A	110	Analyst Forecast Gap Up
KRYS Krystal Biotech	4.1151 of 5 stars	$334.34 -0.4%	$365.40 +9.3%	+130.3%	$9.96B	$440.48M	42.16	210	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KOD) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kodiak Sciences (KOD) Competitors

KOD vs. PTGX, KYMR, SMMT, KRYS, and NUVL

How does Kodiak Sciences compare to Protagonist Therapeutics?

Summary

How does Kodiak Sciences compare to Kymera Therapeutics?

Summary

How does Kodiak Sciences compare to Summit Therapeutics?

Summary

How does Kodiak Sciences compare to Krystal Biotech?

Summary

How does Kodiak Sciences compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kodiak Sciences (KOD) Competitors

KOD vs. PTGX, KYMR, SMMT, KRYS, and NUVL

How does Kodiak Sciences compare to Protagonist Therapeutics?

Is KOD or PTGX more profitable?

Do institutionals and insiders have more ownership in KOD or PTGX?

Does the media favor KOD or PTGX?

Do analysts recommend KOD or PTGX?

Which has stronger earnings & valuation, KOD or PTGX?

Which has more risk & volatility, KOD or PTGX?

Summary

How does Kodiak Sciences compare to Kymera Therapeutics?

Do analysts rate KYMR or KOD?

Do insiders & institutionals believe in KYMR or KOD?

Which has more risk & volatility, KYMR or KOD?

Which has higher valuation & earnings, KYMR or KOD?

Is KYMR or KOD more profitable?

Does the media prefer KYMR or KOD?

Summary

How does Kodiak Sciences compare to Summit Therapeutics?

Do insiders and institutionals hold more shares of KOD or SMMT?

Which has more risk & volatility, KOD or SMMT?

Do analysts prefer KOD or SMMT?

Is KOD or SMMT more profitable?

Does the media favor KOD or SMMT?

Which has stronger valuation and earnings, KOD or SMMT?

Summary

How does Kodiak Sciences compare to Krystal Biotech?

Which has more volatility & risk, KOD or KRYS?

Is KOD or KRYS more profitable?

Does the media favor KOD or KRYS?

Which has better valuation & earnings, KOD or KRYS?

Do insiders & institutionals hold more shares of KOD or KRYS?

Do analysts prefer KOD or KRYS?

Summary

How does Kodiak Sciences compare to Nuvalent?

Is NUVL or KOD more profitable?

Does the media favor NUVL or KOD?

Which has more volatility and risk, NUVL or KOD?

Do analysts prefer NUVL or KOD?

Which has higher earnings and valuation, NUVL or KOD?

Do institutionals and insiders hold more shares of NUVL or KOD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools